Stoke Therapeutics Inc (STOK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stoke Therapeutics Inc (STOK) Competitors
The companies most similar to Stoke Therapeutics are Structure Therapeutics Inc. American Depositary Shares (GPCR), Sarepta Therapeutics (SRPT) and Beam Therapeutics (BEAM). By market cap, Stoke Therapeutics ranks 4th of the 13 companies on this page; Dyne Therapeutics (DYN) is the largest at $3.22B.
Peer Comparison
STOK's revenue growth of 5.9% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics (STOK) | $1.75B | N/A | 64.5x | 0.0% | N/A | 5.9% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Sarepta Therapeutics Inc (SRPT) | $1.72B | N/A | 0.8x | -5.9% | -3.2% | -4.5% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Verastem Inc (VSTM) | $1.03B | N/A | 7.8x | -178.4% | -110.4% | 113.6% | 0.00% |
| Dyne Therapeutics Inc (DYN) | $3.22B | N/A | N/A | 0.0% | -42.9% | 0.0% | 0.00% |
| Alto Neuroscience, Inc. (ANRO) | $1.18B | N/A | N/A | 0.0% | -23.5% | 0.0% | 0.00% |
| Sellas Life Sciences Group Inc (SLS) | $1.60B | N/A | N/A | 0.0% | N/A | -82.5% | 0.00% |
| Taysha Gene Therapies Inc (TSHA) | $1.34B | N/A | 300.6x | 0.0% | -32.8% | 171.3% | 0.00% |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Harmony Biosciences Holdings (HRMY) | $1.98B | 9.6x | 1.9x | 18.0% | 13.7% | 12.3% | 0.00% |
| Forte Biosciences Inc (FBRX) | $1.63B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $1.52B | 9.6x | 11.4x | 0.0% | -31.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Stoke Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Sarepta Therapeutics Inc (SRPT) | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy... | SRPT competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| Verastem Inc (VSTM) | Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. | VSTM competitors |
| Dyne Therapeutics Inc (DYN) | Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases... | DYN competitors |
| Alto Neuroscience, Inc. (ANRO) | Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. | ANRO competitors |
| Sellas Life Sciences Group Inc (SLS) | SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications... | SLS competitors |
| Taysha Gene Therapies Inc (TSHA) | Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies... | TSHA competitors |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular... | MLYS competitors |
| Harmony Biosciences Holdings (HRMY) | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. | HRMY competitors |
| Forte Biosciences Inc (FBRX) | Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California. |
Frequently Asked Questions About STOK
Who are Stoke Therapeutics' main competitors?
The companies most similar to Stoke Therapeutics include Structure Therapeutics Inc. American Depositary Shares (GPCR), Sarepta Therapeutics (SRPT), Beam Therapeutics (BEAM), Silence Therapeutics (SLN) and Verastem (VSTM), listed from the closest match.
Who is Stoke Therapeutics' biggest competitor?
Dyne Therapeutics (DYN) is the largest of the similar companies at $3.22B; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the closest match by business profile, size, sector and industry.
How does STOK stock compare with its competitors?
STOK's P/S is 64.5x against a peer median of 11.4x; its net margin is 0.0% against a peer median of 0.0%.
Which of Stoke Therapeutics' competitors pays a higher dividend?
Stoke Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Stoke Therapeutics bigger than its competitors?
No. Stoke Therapeutics is 4th by market cap among the 13 companies on this page; the largest is Dyne Therapeutics (DYN) at $3.22B.
STOK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors